Join our webinar to discover how to de-risk ADC development through the integration of AI-driven analytics, mouse clinical trials and specialized translational models.
Antibody-Drug Conjugates represent one of the fastest-growing therapeutic modalities in oncology, combining the specificity of monoclonal antibodies with the potency of cytotoxic payloads. Despite significant commercial and clinical success, ADC development remains highly complex. Challenges include target selection, linker stability, payload toxicity, resistance mechanisms, biomarker identification, and limited predictability of preclinical efficacy models. Many ADC programs demonstrate promising preclinical data yet encounter unexpected toxicity, insufficient efficacy, or resistance in clinical trials.
Bridging the gap between preclinical modeling and clinical performance requires more sophisticated and translationally relevant strategies. In this webinar, we will discuss how AI-enabled data mining and predictive modeling can support rational ADC design and biomarker discovery. We will also explore the value of mouse clinical trial platforms and ADC-resistant tumor models in understanding treatment response, resistance mechanisms, and combination strategies. By integrating advanced computational approaches with clinically relevant in vivo systems, we aim to improve translational confidence and accelerate decision-making in ADC development programs.
Presenters
Simon Jiang
With three successful IND submissions, Dr. Simon Jiang intimately understands ADCs, the pressures of deadlines, funding challenges and regulatory expectations. He leads Scientific Engagement at LIDE, serving as a scientific thought partner for LIDE’s clients.
Luke Piggott
Dr. Luke Piggott leads the preclinical and clinical pharmacology programs at Debiopharm. He focuses on leveraging advanced technologies like artificial intelligence to accelerate the development of targeted therapies. He has worked with DNA damage response (DDR) inhibitors and exploring novel-novel drug combinations to address high unmet medical needs.
Sponsor
Shanghai LIDE Biotech Co., Ltd. (LIDE Biotech)
Content Partners
Scientist.com
Scientist.com is the world’s largest and first platform built for the intricacies of scientific outsourcing.
We help pharmaceutical and biotechnology organizations discover, engage, manage, and scale relationships with the providers that support every stage of the pipeline—from discovery and preclinical research to clinical development, manufacturing, medical affairs, and commercialization. Through a centralized platform, organizations can access a global network of 6,000+ providers, streamline sourcing and procurement workflows, maintain compliance, manage supplier relationships, and leverage data-driven insights to make faster, more informed decisions.
Today, Scientist.com supports more than 130 life science organizations, including 24 of the world's top 30 pharmaceutical companies, helping teams reduce operational complexity, accelerate timelines, and bring innovations to patients faster. Our mission is to make it possible to cure all human disease by 2050.
